MAP2K2 and Nephroblastoma: Therefore, in this study we used U0126, a highly selective inhibitor of MEK1 and MEK2 [21], to assess its therapeutic efficacy in this Wilms tumor model and to investigate whether the U0126 would induce changes in tumor glycolytic activity that can be used as a potential pharmacodynamic biomarker.